← Back to headlines
Maze Therapeutics Stock Declines Despite Positive Trial Data
Maze Therapeutics experienced a fall in its stock value, even after announcing positive mid-stage trial data for its lead asset.
25 Mar, 15:38 — 25 Mar, 15:38
Sources
Showing 1 of 1 sources
